By proceeding, you agree to our Terms of Use and Privacy Policy.
Carterra is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates.
20-22 September 2022
The Newly Re-Branded 13th World Multispecifics Summit is the Only End-to-End Meeting Committed Solely to Advancing the Development of Bi- & Multi-Specific Therapeutics With more clinical candidates and commercial success than ever within this rapidly
Event Ended
USA
Paid
Boston
12-14 October 2022
Over the past 10 years, CHI's Immuno-Oncology Summit has become the leading annual meeting focusing on the latest applied research, providing comprehensive and in-depth coverage across all modalities and stages in the pipeline.
Hybrid
17-20 October 2022
Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules. We
14-16 November 2022
Network with more than 1,000 colleagues at PEGS Europe, the largest protein & antibody engineering event in Europe, which has been described as "the best biologics technology meeting in Europe.
Spain
Barcelona
04-08 December 2022
THE #1 ANTIBODY ENGINEERING CONFERENCE FOR ACCELERATING NEXT GENERATION ANTIBODIES TO COMMERCIAL SUCCESS Brand New Session Themes for 2022: How to Develop an Antibody-based Drug from Discovery to IND? Adaptive Immune Receptor Repertoire Data Processi
San Diego
20-22 March 2023
The Festival of Biologics brings together pharma & biotech, academics and research institutes, together with their partners across the value chain.
02-04 October 2023
Join us for the 14th World Bispecific Summit in 2023, where we celebrate the remarkable advancements and immense potential of bispecific antibody treatments. In this pivotal year, bispecific antibody therapies have emerged as formidable contenders in
13-16 December 2023
The latest science and research on antibody engineering, design and selection diving into critical topics including Neurodegenerative Diseases, Tumor Microenvironment in Antibody Therapy, Antibody Immune Agonist, Bi-Specifics, ADCs, Protein-Based Deg